IP Library › Granted Patent US 10,548,896
Granted Patent B2
US 10,548,896 · App. 16/387,318 · Granted Feb 4, 2020

Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas

Inventors: Jiangchun Xu (San Diego, CA); Robert Cho (Sunnyvale, CA); Aaron Nguyen (San Jose, CA)
Assignee: Celgene Quanticel Research, Inc.
A61K31/513A61K31/357A61K31/436A61K31/5377A61K31/551A61K31/5685A61K31/7048A61P35/00C07D401/04C07D401/14C07D405/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,548,896
App. No.
16/387,318
Granted
Feb 4, 2020
Kind
B2
Abstract

Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).

Claims (6)

1. A method for the treatment of gastric neuroendocrine carcinoma comprising the administration to a patient in need thereof an effective amount of a compound having the structure of:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the administration is affected by oral administration.

3. The method of claim 1 , wherein the effective amount of the compound comprises about 1.5 mg/kg to about 10 mg/kg.

4. The method of claim 1 , wherein the compound is in the form of a tablet, pill, sachet, or capsule of hard or soft gelatin.

5. The method of claim 1 , wherein the compound is in the form of a capsule containing the compound at dosage strengths comprising about 0.50 mg, 0.75 mg, or 2.00 mg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2019
From: CELGENE CORPORATION
To: CELGENE QUANTICEL RESEARCH, INC.
Reel/Frame 050974/0894 →
Continuity (4)
Continuation 15673084 · Aug 9, 2017
Provisional Application 62373263 · Aug 10, 2016
Provisional Application 62468424 · Mar 8, 2017
Related Publication 20190240223A1 · Aug 8, 2019